Key facts
- This page summarizes Claude Nicaise's Form 4 filing for Sarepta Therapeutics, Inc. (SRPT).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Mar 2025, 20:00.
Claude Nicaise - 12 Mar 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)
- Reporting relationship
- Director
- Issuer ticker
- SRPT
- Reported as of
- 12 Mar 2025
- Net transaction value
- -$2,799
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2025, 20:00:04 UTC
- Prior SEC filing
- 11 Mar 2025
- Next SEC filing
- 27 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cristin Rothfuss, as Attorney-in-Fact for Claude Nicaise
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Claude Nicaise filed Form 4 for Sarepta Therapeutics, Inc. (SRPT) on 13 Mar 2025.
Change
- Previous filing in this sequence was filed on 11 Mar 2025.
- Current net transaction value: -$2,799.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SRPT
transaction
Common Stock
Options Exercise
- Transaction value
- $245,404
- Shares
- +9,746
- Change %
- +47%
- Price
- $25.18
- Shares after
- 30,303
- Date
- 12 Mar 2025
- Ownership
- Direct
SRPT
transaction
Common Stock
Sale
- Transaction value
- $248,203
- Shares
- -2,491
- Change %
- -8.2%
- Price
- $99.64
- Shares after
- 27,812
- Date
- 12 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SRPT
transaction
Derivative
Stock Options (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -9,746
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,746
- Exercise price
- $25.18
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares were sold to cover the exercise price relating to the exercise of stock options to purchase shares, which are scheduled to expire in 2025.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.64 and $99.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.